Published on
December 9, 2025
- 12:00 GMT
ReEngage Therapeutics Announces Method of Use Patent Covering ACSS2 Inhibitors and their Use in Many Disorders
Patent covers multiple uses of novel class of small molecule therapies HOUSTON, TX, UNITED STATES, December 9, 2025 /EINPresswire.com/ -- ReEngage Therapeutics, a clinical-stage pharmaceutical company pioneering epigenetics to treat cancer and other …
Distribution channels:
Business & Economy, Healthcare & Pharmaceuticals Industry
...
